Any grades of hematological toxicity | ||||||||
 |  |  | Neutropenia | Thrombocytopenia | Anemia | |||
Median age (years) | < 45 | ratea | 82% (42–100%) | P > 0.05 | 74% (44–95%) | P > 0.05 | 79% (4–100%) | P > 0.05 |
Nb | 146 | 156 | 65 | |||||
≥45 and < 60 | rate | 82% (64–96%) | 57% (39–75%) | 77% (59–92%) | ||||
N | 565 | 605 | 580 | |||||
> 60 | rate | 72% (56–85%) | 50% (28–71%) | 53% (39–68%) | ||||
N | 428 | 443 | 443 | |||||
Pathological type | leukemia | rate | 62% (17–98%) | P > 0.05 | 60% (22–93%) | P > 0.05 | 69% (17–100%) | P > 0.05 |
N | 244 | 254 | 176 | |||||
lymphoma | rate | 83% (73–90%) | 60% (46–73%) | 68% (54–80%) | ||||
N | 737 | 742 | 721 | |||||
MM | rate | 88% (64–100%) | 57% (36–77%) | 53% (21–84%) | ||||
N | 132 | 182 | 136 | |||||
Targeting antigen | CD19 | rate | 73% (58–86%) | P = 0.0001 | 56% (40–71%) | P > 0.05 | 64% (48–79%) | P > 0.05 |
N | 918 | 933 | 834 | |||||
non-CD19 | rate | 93% (84–99%) | 70% (54–83%) | 74% (46–95%) | ||||
N | 278 | 328 | 282 | |||||
Proportion of previous HSCT | < 50% | rate | 80% (56–97%) | P > 0.05 | 74% (58–87%) | P > 0.05 | 74% (58–87%) | P > 0.05 |
N | 978 | 1071 | 973 | |||||
≥50% | rate | 77% (62–89%) | 52% (34–69%) | 49% (23–74%) | ||||
N | 94 | 94 | 94 | |||||
Median lines of prior therapy | < 4 | rate | 79% (61–93%) | P > 0.05 | 42% (27–58%) | P = 0.0252 | 55% (43–67%) | P > 0.05 |
N | 673 | 707 | 690 | |||||
≥4 | rate | 81% (69–92%) | 67% (53–80%) | 65% (43–84%) | ||||
N | 267 | 288 | 238 | |||||
Co-stimulatory molecule | CD28 | rate | 88% (82–93%) | P > 0.05 | 79% (59–94%) | P = 0.0054 | 79% (64–92%) | P = 0.0274 |
N | 207 | 207 | 207 | |||||
41BB | rate | 65% (41–86%) | 36% (17–57%) | 55% (42–67%) | ||||
N | 463 | 453 | 453 | |||||
Median age in leukemia cases | < 20 | rate | 61% (10–100%) | P > 0.05 | 45% (14–79%) | P = 0.032 | No analysis | |
N | 60 | 60 | ||||||
≥20 | rate | 83% (38–100%) | 87% (66–99%) | |||||
N | 94 | 104 | ||||||
Median age in lymphoma cases | < 60 | rate | 85% (63–99%) | P > 0.05 | 59% (35–81%) | P > 0.05 | 80% (64–93%) | P = 0.0424 |
N | 404 | 394 | 394 | |||||
≥60 | rate | 67% (51–81%) | 47% (23–72%) | 52% (34–69%) | ||||
N | 395 | 410 | 410 | |||||
≥3 grade of hematological toxicity | ||||||||
 |  |  | Neutropenia | Thrombocytopenia | Anemia | |||
Median age (years) | < 45 | rate | 57% (28–84%) | P > 0.05 | 33% (20–47%) | P > 0.05 | 38% (22–56%) | P > 0.05 |
N | 314 | 374 | 261 | |||||
≥45 and < 60 | rate | 59% (40–76%) | 32% (22–43%) | 34% (22–46%) | ||||
N | 592 | 662 | 645 | |||||
> 60 | rate | 59% (45–71%) | 32% (23–43%) | 28% (18–40%) | ||||
N | 531 | 514 | 546 | |||||
Pathological type | leukemia | rate | 48% (22–76%) | P > 0.05 | 28% (16–42%) | P > 0.05 | 41% (28–54%) | P > 0.05 |
N | 390 | 450 | 350 | |||||
lymphoma | rate | 60% (49–71%) | 32% (25–40%) | 24% (16–34%) | ||||
N | 985 | 825 | 979 | |||||
MM | rate | 58% (29–84%) | 40% (28–53%) | 31% (15–50%) | ||||
N | 215 | 261 | 350 | |||||
Targeting antigen | CD19 | rate | 52% (40–64%) | P = 0.0088 | 29% (22–36%) | P > 0.05 | 28% (21–35%) | P > 0.05 |
N | 1313 | 1221 | 1267 | |||||
non-CD19 | rate | 75% (57–90%) | 43% (32–54%) | 42% (24–62%) | ||||
N | 339 | 398 | 371 | |||||
Proportion of previous HSCT | < 50% | rate | 58% (44–71%) | P > 0.05 | 33% (26–41%) | P > 0.05 | 36% (26–45%) | P > 0.05 |
N | 1093 | 1180 | 1146 | |||||
≥50% | rate | 59% (34–82%) | 30% (16–46%) | 34% (19–50%) | ||||
N | 258 | 239 | 183 | |||||
Median lines of prior therapy | < 4 | rate | 53% (38–68%) | P > 0.05 | 28% (20–36%) | P > 0.05 | 32% (25–39%) | P > 0.05 |
N | 961 | 924 | 999 | |||||
≥4 | rate | 60% (46–73%) | 34% (24–43%) | 24% (13–36%) | ||||
N | 419 | 440 | 390 | |||||
Co-stimulatory molecule | CD28 | rate | 47% (34–66%) | P > 0.05 | 47% (34–60%) | P = 0.0004 | 29% (18–41%) | P > 0.05 |
N | 405 | 238 | 405 | |||||
41BB | rate | 53% (38–74%) | 18% (10–27%) | 22% (11–34%) | ||||
N | 471 | 463 | 471 | |||||
Median age in leukemia cases | < 20 | rate | 46% (18–75%) | P > 0.05 | 23% (10–40%) | P > 0.05 | 36% (18–70%) | P > 0.05 |
N | 186 | 178 | 65 | |||||
≥20 | rate | 58% (11–97%) | 37% (20–56%) | 42% (28–65%) | ||||
N | 114 | 182 | 174 | |||||
Median age in lymphoma cases | < 60 | rate | 64% (45–82%) | P > 0.05 | 32% (22–44%) | P > 0.05 | 31% (19–43%) | P > 0.05 |
N | 485 | 477 | 485 | |||||
≥60 | rate | 49% (32–67%) | 27% (16–40%) | 22% (12–34%) | ||||
N | 562 | 410 | 577 | |||||
Median age in MM cases | < 60 | rate | 34% (14–57%) | P = 0.0227 | 29% (16–44%) | P = 0.0356 | 26% (9–48%) | P > 0.05 |
N | 58 | 136 | 119 | |||||
≥60 | rate | 73% (47–93%) | 48% (37–58%) | 48% (18–79%) | ||||
N | 95 | 84 | 95 |